全文获取类型
收费全文 | 45333篇 |
免费 | 3122篇 |
国内免费 | 172篇 |
专业分类
耳鼻咽喉 | 486篇 |
儿科学 | 1054篇 |
妇产科学 | 900篇 |
基础医学 | 5433篇 |
口腔科学 | 1167篇 |
临床医学 | 4771篇 |
内科学 | 9536篇 |
皮肤病学 | 495篇 |
神经病学 | 3610篇 |
特种医学 | 1527篇 |
外国民族医学 | 1篇 |
外科学 | 7630篇 |
综合类 | 714篇 |
一般理论 | 26篇 |
预防医学 | 3587篇 |
眼科学 | 1289篇 |
药学 | 3026篇 |
中国医学 | 55篇 |
肿瘤学 | 3320篇 |
出版年
2023年 | 211篇 |
2022年 | 367篇 |
2021年 | 855篇 |
2020年 | 516篇 |
2019年 | 754篇 |
2018年 | 913篇 |
2017年 | 650篇 |
2016年 | 768篇 |
2015年 | 887篇 |
2014年 | 1292篇 |
2013年 | 1981篇 |
2012年 | 2846篇 |
2011年 | 2953篇 |
2010年 | 1676篇 |
2009年 | 1537篇 |
2008年 | 2673篇 |
2007年 | 2794篇 |
2006年 | 2778篇 |
2005年 | 2926篇 |
2004年 | 2808篇 |
2003年 | 2601篇 |
2002年 | 2452篇 |
2001年 | 546篇 |
2000年 | 460篇 |
1999年 | 555篇 |
1998年 | 591篇 |
1997年 | 473篇 |
1996年 | 413篇 |
1995年 | 397篇 |
1994年 | 324篇 |
1993年 | 308篇 |
1992年 | 339篇 |
1991年 | 277篇 |
1990年 | 267篇 |
1989年 | 250篇 |
1988年 | 234篇 |
1987年 | 235篇 |
1986年 | 212篇 |
1985年 | 239篇 |
1984年 | 307篇 |
1983年 | 308篇 |
1982年 | 395篇 |
1981年 | 360篇 |
1980年 | 329篇 |
1979年 | 191篇 |
1978年 | 222篇 |
1977年 | 222篇 |
1976年 | 206篇 |
1975年 | 170篇 |
1973年 | 166篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
ABSTRACTIn clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the test treatment under study. For example, in cancer clinical trials, overall survival, response rate, and/or time to disease progression are usually considered as primary clinical endpoints for evaluation of safety and effectiveness of the test treatment under investigation. Once the study endpoints have been selected, sample size required for achieving a desired power is then determined. It, however, should be noted that different study endpoints may result in different sample sizes. In practice, it is usually not clear which study endpoint can best inform the disease status and measure the treatment effect. Moreover, different study endpoints may not translate one another although they may be highly correlated one another. In this article, we intend to develop an innovative endpoint namely therapeutic index based on a utility function to combine and utilize information collected from all study endpoints. Statistical properties and performances of the proposed therapeutic index are evaluated theoretically. A numerical example concerning a cancer clinical trial is given to illustrate the use of the proposed therapeutic index. 相似文献
3.
The human visual system is amenable to a number of adaptive processes; one such process, or collection of processes, is the adaptation to blur. Blur adaptation can be observed as an improvement in vision under degraded conditions, and these changes occur relatively rapidly following exposure to blur. The potential important future directions of this research area and the clinical implications of blur adaptation are discussed. 相似文献
4.
5.
6.
7.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
8.
9.